The present application has specification that builds upon U.S. Provisional Application No. 62/185,769, filed Jun. 29, 2015, and PCT/US16/19282 filed Feb. 24, 2016, the disclosures of which are hereby incorporated herein by reference in their entirety.
Sweat sensing technologies have enormous potential for applications ranging from athletics, to neonatology, to pharmacological monitoring, to personal digital health, to name a few applications. Sweat contains many of the same biomarkers, chemicals, or solutes that are carried in blood and can provide significant information enabling one to diagnose illness, health status, exposure to toxins, performance, and other physiological attributes even in advance of any physical sign. Furthermore, sweat itself, the action of sweating, and other parameters, attributes, solutes, or features on, near, or beneath the skin can be measured to further reveal physiological information.
Sweat biosensing applications have largely remained relegated to infant chloride assays for Cystic Fibrosis or illicit drug monitoring patches. This is because the majority of medical literature on sweat biomarkers relies on a slow and inconvenient process of sweat stimulation, collection of a sample, transport of the sample to a lab, and then analysis of the sample by a bench-top machine and a trained expert. This process is so labor intensive, complicated, and costly that a blood draw is usually a superior testing modality, since it is the gold standard for most high performance biomarker sensing. Hence, sweat sensing has yet to realize its full biosensing potential, especially for continuous or repeated biosensing. Furthermore, attempts to use sweat sensing to measure “holy grails” like glucose have thus far failed to produce viable commercial products, reducing the perceived capability and opportunity space for sweat sensing.
Among the physiological fluids used for bio monitoring (e.g. blood, urine, saliva, tears), sweat has arguably the least predictable sampling rate in the absence of technology. However, with proper application of technology, sweat can be made to outperform other non-invasive or less invasive biofluids in predictable sampling. For example, it is difficult to control saliva or tear rate without negative consequences for the user (e.g., dry eyes, tears, dry mouth, or excessive saliva while talking). Urine is also a difficult fluid for physiological monitoring, because it is inconvenient to take multiple urine samples, it is not always possible to take a urine sample when needed, and control of biomarker dilution in urine imposes further significant inconveniences on the user or test subject.
By contrast, as disclosed in herein, sweat may be stimulated and sampled when needed, and sweat rates may be controlled for particular applications. For instance, some biomarkers diffuse into sweat at known rates, and these rates will correspond to a particular sweat rate that allows the biomarker's sweat concentration to optimally correlate to its concentration in blood. (e.g., too high of a sweat rate will dilute a biomarker concentration as the biomarker may not have time to equilibrate by diffusion into sweat). An excellent summary is provided by Sonner, et al. in the 2015 article titled “The microfluidics of the eccrine sweat gland, including biomarker partitioning, transport, and biosensing implications”, Biomicrofluidics 9, 031301, herein included by reference.
Many of the drawbacks and limitations stated above can be resolved by creating novel and advanced interplays of chemicals, materials, sensors, electronics, microfluidics, algorithms, computing, software, systems, and other features or designs, in a manner that affordably, effectively, conveniently, intelligently, or reliably brings sweat sensing and stimulating technology into intimate proximity with sweat as it is generated. With the improvements embodied in the current invention, sweat sensing can become a compelling new paradigm as a biosensing platform.
The disclosed invention provides a sweat sensor device capable of smart sweat stimulation and sensing. The disclosed devices and methods improve the dependability and predictability of sweat sampling rates; achieve a desired number of sweat sampling events per day while minimizing skin irritation; and use physical, optical or thermal sweat stimulation to augment or replace chemical sweat stimulation.
The objects and advantages of the disclosed invention will be further appreciated in light of the following detailed descriptions and drawings in which:
“Continuous monitoring” means the capability of a device to collect sweat continuously or in multiple samples and provide at least one measurement of a characteristic of that sweat, or to provide a plurality of measurements of the sweat over time.
“Chronological assurance” means a sampling rate or sampling interval for measurement(s) of sweat, or solutes in sweat, at which measurements can be made of new sweat or its new solutes as they originate from the body. Chronological assurance may also include a determination of the effect of sensor function, or potential contamination with previously generated sweat, previously generated solutes, other fluid, or other measurement contamination sources for the measurement(s).
“Determined” may encompass more specific meanings including but not limited to: something that is predetermined before use of a device; something that is determined during use of a device; something that could be a combination of determinations made before and during use of a device.
“Sweat sampling rate” means the effective rate at which new sweat or sweat solutes, originating from the sweat gland or from skin or tissue, reaches a sensor which measures a property of sweat or its solutes. Sweat sampling rate, in some cases, can be far more complex than just sweat generation rate. Sweat sampling rate directly determines or is a contributing factor in determining the chronological assurance. Times and rates are inversely proportional (rates having at least partial units of 1/seconds), therefore a short or small time required to refill a sweat volume can also be said to have a fast or high sweat sampling rate. The inverse of sweat sampling rate (1/s) could also be interpreted as a “sweat sampling interval”. Sweat sampling rates or intervals are not necessarily regular, discrete, periodic, discontinuous, or subject to other limitations. Like chronological assurance, sweat sampling rate may also include a determination of the effect of potential contamination with previously generated sweat, previously generated solutes, other fluid, or other measurement contamination sources for the measurement(s). Sweat sampling rate can also be in whole or in part determined from solute generation, transport, advective transport of fluid, diffusion transport of solutes, or other factors that will impact the rate at which new sweat or sweat solutes reach a sensor and/or are altered by older sweat or solutes or other contamination sources. Sensor response times may also affect sampling rate.
“Sweat stimulation” means the direct or indirect generation of sweat by any external stimulus such as chemical, heat, optical, or other methods, with the external stimulus being applied for the purpose of stimulating sweat. One example of sweat stimulation is the administration of a sweat stimulant such as carbachol, pilocarpine, methylcholine, or other suitable chemical stimulant by iontophoresis, diffusion, injection, ingestion, or other suitable means. Going for a jog, which stimulates sweat, is only sweat stimulation if the individual is jogging for the purpose of stimulating sweat. Sweat stimulation may also include sudo-motor axon reflex sweating, where the stimulation site and sweat generation site are not the same but in close in proximity and physiologically linked in the sweat response.
“Sweat stimulating component” means any component or material that is capable of locally stimulating sweat to a rate greater than the natural local rate would be absent such stimulation.
“Sweat generation rate” means the rate at which sweat is generated by the sweat glands themselves. Sweat generation rate is typically measured by the flow rate from each gland in nL/min/gland. In some cases, the measurement is then multiplied by the number of sweat glands from which the sweat is being sampled.
“Measured” may mean an exact or precise quantitative measurement and can include broader meanings such as, for example, measuring a relative amount of change of something. Measured can also mean a binary measurement, such as ‘yes’ or ‘no’ type measurements.
“Sweat sensor” means any type of sensor that measures in sweat a state, presence, flow rate, solute concentration, or solute presence, in absolute, relative, trending, or other ways. Sweat sensors can include, for example, potentiometric, amperometric, impedance, optical, mechanical, or other means known by those skilled in the art of sensing or biosensing.
A “sweat sampling event” is a sweat sample that is chronologically assured and represents a meaningful measurement. For a continuous flow of sweat, these events are determined by the sweat sampling rate. For a discontinuous flow of sweat, these events correspond to times when sweat volume or sweat generation rate are adequate to make a proper sweat measurement. For example, if a person needed to measure cortisol 3 times per day, then the sweat generation rate would need to be adequate to provide three sweat sampling events, and other times the sweat generation rate could be higher or lower.
“Sweat threshold temperature” or “sweat onset temperature” means an individual's physiological status relative to sweat generation. Specifically, it is the body or skin temperature at which the individual will sweat adequately so that new sweat reaches a sweat sensor. Sweat thresholds and thermal set points for sweat generation vary from individual to individual, and may also vary from day to day for an individual based on factors like hormone levels, age, external temperature, diet, stressors, responsiveness to sweat stimulation, or other factors. Therefore, the sweat onset temperature for an individual may need to be developed prior to device use, during device use, or may need to be estimated based on the individual's phenotype, age, weight, sex, fitness level, or other relevant factor. Important for these purposes, it is typically easier to generate sweat locally when the body is near or above the sweat onset temperature.
“Diffusion” denotes the net movement of a substance from a region of high concentration to a region of low concentration. This is also referred to as the movement of a substance down a concentration gradient.
To better illustrate sweat sampling rate and therefore chronological assurance, this disclosure will first discuss sweat generation rate and sweat volumes. The number of active sweat glands varies greatly among different people, though comparisons between different areas (e.g., axillae versus groin) show the same directional changes (certain areas always have more active sweat glands while others always have fewer). Estimates of the number of glands per cm2 for different areas of the body include: around 370 sweat glands per cm2 for the palm; 200 for the back of the hand; 175 for the forehead; 155 for the chest, abdomen, and forearm; and 60 to 80 for the back and legs. Assuming use of a sweat gland density of 100/cm2, a sensor that is 0.55 cm in radius (1.1 cm in diameter) would cover about 1 cm2 area, or approximately 100 sweat glands.
Now, consider some sweat generation rates provided from Dermatology: an illustrated color text, 5th ed. The human body excretes a minimum of 0.5 L per day of sweat, has 2.5 million sweat glands on average, and there are 1440 minutes per day. (These values are typically lower for prepubescent children.) Divided among 2.5 million glands, that is rate of 0.2 μL/day/gland or 0.14 nL/min/gland. As another example, the PharmCheck patch, a device that determines the presence of illicit substances, claims the patch collects 2 mL per week, which corresponds to a minimum sweat rate of ˜0.1 to 0.2 nL/min/gland in locations with ˜100 glands/cm2. Importantly, this number excludes trans-epidermal water loss, which would not provide the solute concentrations that sweat would provide. This is the minimum ‘average’ sweat generation rate, with some possible exceptions being where sweating naturally increases slightly (such as during sleep cycles, etc.). The maximum sweat generated per person per day is 10 L, which on average is 4 μl, per gland maximum per day, or about 3 nL/min/gland. This is about 20× higher than the minimum sweat generation rate. Both higher and lower rates have been reported and are possible for minimum and maximum sweat rates.
First we return to the assumed sweat gland density of 100/cm2, and the 1 cm2 area sensor that covers approximately 100 sweat glands. Next, assume a sweat volume under the sensor (space between the sensor and the skin) of 50 μm average height or 50E-4 cm, and that same 1 cm2 area, which provides a sweat volume of 50E-4 cm3 or about 50E-4 mL or 5 μL of volume. With the maximum sweat generation rate of 5 nL/min/gland and 100 glands, it would require a 10 minutes to fully refresh the sweat volume (using first principles/simplest calculation only). With the minimum sweat generation rate of 0.1 nL/min/gland and 100 glands, it would require 500 minutes, or 8 hours, to fully refresh the sweat volume. If the sweat volume could be reduced by 10× to an effective volume height of roughly 5 μm, the minimum and maximum times required to fully refresh the sweat volume would be 1 minute and 1 hour, respectively, but the minimum time would also be subject to diffusion and other contamination issues (and 5 μm volume height would be technically challenging). Times and rates are inversely proportional (rates having at least partial units of 1/s), therefore a short time required to refill the sweat volume can also be said to have a fast or high sweat sampling rate.
The above examples may be interpreted to provide a chronologically assured sampling interval for sweat, that is, the sampling interval would be the time needed for sweat to fill, or refill, the sweat volume space. Further, because the sweat in the sweat volume space is prone to significant diffusion, mixing, and contamination, such factors may also partially determine sampling interval. The sampling interval could therefore also be more broadly interpreted to include relevant transport, diffusion, or contamination times. It is clear that for many applications, a relatively dependable or predictable sampling rate is required.
In addition to sampling intervals, sweat generation rate per gland may also affect the collection of meaningful physiological information for certain biomarkers. Many biomarker concentrations in sweat exhibit dependence on sweat rate. For example, sweat concentrations of Na+ and Cl— increase with increasing sweat rate because the sweat glands actively generate these ions when producing sweat. Other large or low lipophilic molecules, like cytokines, decrease in concentration as sweat rates increase because these molecules diffuse passively into sweat. At high sweat rates, therefore, there is insufficient time for diffusion to maintain concentrations in sweat that correlate to those in blood. For these molecules, prolonged sweat stimulation at low sweat rates may be necessary. It is clear that for many applications, a relatively dependable or predictable sweat generation rate per gland is required.
The present disclosure applies at least to any type of sweat sensor device that stimulates and measures sweat, sweat generation rate, sweat chronological assurance, its solutes, solutes that transfer into sweat from skin, a property of or things on the surface of skin, or properties or things beneath the skin. The present disclosure applies to sweat sensing devices which can take on forms including patches, bands, straps, portions of clothing, wearables, or any suitable mechanism that reliably brings sweat stimulating, sweat collecting, and/or sweat sensing technology into intimate proximity with sweat as it is generated. Some embodiments utilize adhesives to hold the device near the skin, but devices could also be held by other mechanisms that hold the device secure against the skin, such as a strap or embedding the device in a helmet.
Certain embodiments of the present disclosure show sensors as simple individual elements. It is understood that many sensors require two or more electrodes, reference electrodes, or additional supporting technology or features that are not captured in the description herein. Sensors are preferably electrical in nature, but may also include optical, chemical, mechanical, or other known biosensing mechanisms. Sensors can be in duplicate, triplicate, or more, to provide improved data and readings. Sensors may be referenced herein by what the sensor is sensing, for example: a sweat sensor; an impedance sensor; a sweat volume sensor; a sweat generation rate sensor; a solute generation rate sensor, a galvanic skin response sensor, and so on. Certain embodiments of the invention show sub-components of what would be sweat sensing devices with more sub-components needed for use of the device in various applications, which are obvious (such as a battery), and for purpose of brevity and focus on inventive aspects, are not explicitly shown in the diagrams or described in the embodiments of the disclosure.
Specifically, the present disclosure provides smart sweat stimulation and sensing embodiments, which improve the dependability and predictability of sweat sampling rates; achieve a desired number of sweat sampling events per day while minimizing skin irritation; and use physical, optical or thermal sweat stimulation to augment or replace chemical sweat stimulation.
Sweat stimulation, or sweat activation, can be achieved by known methods. For example, sweat may be stimulated thermally (via infrared light, or a thermal wrap, for example), by orally administering a drug, by intradermal injection of drugs such as carbachol, methylcholine, or pilocarpine, by introduction of a sweat stimulant by diffusion, and by dermal introduction of such drugs using iontophoresis. A device for iontophoresis may, for example, provide direct current into the skin and use large lead electrodes lined with porous material, where the positive pole is dampened with 2% pilocarpine hydrochloride and the negative pole with 0.9% NaCl solution. Sweat can also be controlled or created by asking the device wearer to engage in or increase activities or conditions that cause them to sweat. Other sweat stimulants and stimulation techniques are also possible and known in the art.
The sweat sensor device may be configured to measure sweat rate, for example by using skin impedance or galvanic skin response (GSR), or by measuring Na+, Cl—, and K+ ratios emerging in sweat, or by other means. With a sweat rate measurement, the sweat sensing device may then adjust sweat stimulation to enable a sweat sensing event, or to control for a target sweat generation rate. These techniques may be referred to as active control of sweat generation rate.
In addition to allowing control of sweat generation rates, the disclosed invention also allows sweat stimulation to be applied more efficiently, which may prolong the life of the device through longer battery life or less use of stimulation chemicals. More efficient stimulation also reduces irritation to the wearer's skin that may be caused by the heat, electricity, or chemicals used to stimulate sweat. In general, stimulating sweat when the skin temperature is close to the sweat generation threshold is more efficient than at other times, so the device could be configured to initiate stimulation only when measured skin temperature is naturally close to sweat onset, or the device may instruct the user to increase skin temperature, for example by taking a walk. The device itself may also be configured to increase local skin temperature, for example, by using a thermally insulating layer to seal with the skin around the device. In this way, the seal can create a local environment under the patch with a higher skin temperature in which the sweat glands generate sweat more easily than they would outside the patch. In some cases, this may eliminate the need for any further stimulation. In other cases, it should reduce the amount of stimulation required.
In some embodiments, a device utilizing both a thermal stimulation means, such as an infrared light source, and a chemical stimulation means, such as carbachol or pilocarpine, may provide improved efficiency and reduced skin irritation, e.g., by allowing each means to operate for shorter duration or at lower intensity. Combined use may also allow improved operation on other measures, for example by allowing the sweat sensor device to generate sweat from a lower sweat onset temperature, or by providing redundancy in the event that either means malfunctions, or the skin stops responding to one form of stimulation or the other.
With reference to
With reference to
With reference to
The following examples are provided to help illustrate the disclosed invention, and are not comprehensive or limiting in any manner.
An individual wears a sweat sensing device similar to that depicted in
A particular sweat sensor application requires four sweat sampling events per day, at an interval of at least two hours between sampling events. Using continual thermal stimulation to support the application would be ineffective, either because the body may adapt to the thermal stimulation by reducing the sweat response, because continuous thermal stimulation would cause excessive skin irritation, or because such stimulation would be an excessive drain on electronic power or onboard stimulant resources. The sweat sensing device could determine the sweat onset temperature directly by skin impedance, or indirectly by room temperature, heart rate, or other means. Alternately, the device may infer through the individual's behavior that they will soon reach sweat onset, for instance, because the individual is taking a walk. The device also measures when the skin under the device is adequately close to sweat onset via skin temperature, GSR, skin impedance, or other means. Once the skin is sufficiently close to the sweat onset, the device stimulates sweat to allow a sweat sampling event to occur. The amount of needed sweat stimulation varies widely, and by non-limiting example could be 1 minute of carbachol iontophoresis, 1 minute of pulsed LED thermal stimulation, or 15 minutes or more of thermal stimulation. The device may have access to, or may develop, a data profile on the individual's responsiveness to sweat stimulation techniques, duration, intensity, amounts, etc., to determine the most efficient sweat stimulation for the individual. The same technique provides value for chemical or other stimulation methods as well. This embodiment generally describes a sweat sensing device that is opportunistic in terms of when to stimulate, sample and sense sweat. Meaning, that it initiates sweat stimulation when it will use the least resources, and cause the least irritation to the wearer.
An individual wearing a sweat sensing device has not yet provided adequate sweat sampling events to enable a particular application. The device communicates to a smart phone, which in turn alerts the user to do something to increase proximity to sweat onset, or alternatively, the device may initiate thermal or chemical sweat stimulation, so that a sweat sampling event can occur. Both inducing sweat directly and improving proximity to sweat onset temperature are distinct embodiments of the disclosed invention. The individual responds to the alert by taking a brisk walk, turning up the room temperature, putting on a sweater, drinking a cup of tea, or other means, to cause a sampling event to occur, or to cause a sweat sampling event to occur by acting in combination with other sweat stimulation techniques. The individual may also orally ingest a chemical sweat stimulant, or other drugs, e.g., pilocarpine, or cevimeline. This embodiment generally describes a sweat sensing device that allows both an opportunistic sweat stimulation strategy, and a proactive sweat stimulation strategy. Meaning, that it instructs the wearer to undertake action(s) that improve their proximity to sweat onset, or initiates artificial sweat stimulation.
Conversely, an individual's sweat generation rate may be too high for a particular application, for example, the detection of a large molecule such as a cytokine (the high sweat rate could make a target analyte very dilute, and thus below sensor detection limits). The sweat sensing device responds by alerting the user that they need to reduce activity, cool themselves, or take other action to lower their sweat generation rate, thereby allowing a meaningful sweat sampling event to occur.
For a particular application, a user is sufficiently below their sweat onset so that the thermal stimulation required to induce sweating would be of excessive intensity or duration, for example, high enough to induce discomfort or cause short or long term injury. To avoid discomfort or negative health effects, the device applies thermal stimulation in short pulses that stimulate sweat but do not raise the time-averaged skin temperature sufficiently to cause negative effects. Infrared and visible wavelengths generally have adequate absorption length into skin for thermal stimulation by light, and light-emitting diodes are capable of rapid pulsing. Scientific literature indicates that thermal nerve stimulation to cause sweating is due to a dimensional thermal gradient (dT/dz) or a temporal thermal gradient (dT/dt), for which pulsed thermal stimulation is therefore likely more effective per unit energy or average skin temperature than constant thermal stimulation. See Jansen, E., “Optical stimulation of neural tissue,” Medical Bionics Conference, Nov. 23, 2011.
A sweat sensing device with an exothermal chemical heat component is configured to stimulate sweat by maintaining a local skin temperature between 100 degrees Fahrenheit (° F.) and 106° F. (temperatures of 107° F. and above correlate with medically-known dangerous fevers and tissue damage). Raising the local skin temperature also increases capillary blood flow to skin and increases the rate of solute diffusion. As disclosed, therefore, thermal sweat stimulation has the additional benefit of increasing the rate of biomarker partitioning into sweat, which may allow shorter sampling intervals or improved solute correlation between sweat and blood.
This has been a description of the disclosed invention along with a preferred method of practicing the invention, however the invention itself should only be defined by the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
4190060 | Greenleaf et al. | Feb 1980 | A |
4542751 | Webster et al. | Sep 1985 | A |
4756314 | Eckenhoff et al. | Jul 1988 | A |
4820263 | Spevak et al. | Apr 1989 | A |
5036861 | Sembrowich et al. | Aug 1991 | A |
5050604 | Reshef et al. | Sep 1991 | A |
5140985 | Schroeder | Aug 1992 | A |
5246003 | Delonzor | Sep 1993 | A |
5437999 | Diebold et al. | Aug 1995 | A |
5438984 | Schoendorfer | Aug 1995 | A |
5556789 | Goerlach-Graw et al. | Sep 1996 | A |
5690893 | Ozawa et al. | Nov 1997 | A |
5814599 | Mitragotri et al. | Sep 1998 | A |
5944662 | Schoendorfer | Aug 1999 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6198953 | Webster et al. | Mar 2001 | B1 |
6256533 | Yuzhakov et al. | Jul 2001 | B1 |
6269265 | Anderson | Jul 2001 | B1 |
6299578 | Kurnik et al. | Oct 2001 | B1 |
6592529 | Marett | Jul 2003 | B2 |
6666821 | Keimel | Dec 2003 | B2 |
6838480 | Wharton | Jan 2005 | B1 |
7044911 | Drinan et al. | May 2006 | B2 |
7190986 | Hannula et al. | Mar 2007 | B1 |
7219534 | Campbell | May 2007 | B2 |
7378054 | Karmali | May 2008 | B2 |
7383072 | Edmonson et al. | Jun 2008 | B2 |
7384396 | Samuels et al. | Jun 2008 | B2 |
7749445 | Masters | Jul 2010 | B2 |
7800494 | Kim | Sep 2010 | B2 |
7813780 | Shah et al. | Oct 2010 | B2 |
7842234 | Lauks et al. | Nov 2010 | B2 |
7959791 | Kjaer et al. | Jun 2011 | B2 |
8125539 | Takashima | Feb 2012 | B2 |
8128889 | Fujimoto et al. | Mar 2012 | B2 |
8252248 | Kramer | Aug 2012 | B2 |
8391946 | Sugenoya et al. | Mar 2013 | B2 |
8565850 | Martinsen et al. | Oct 2013 | B2 |
8593287 | Hayter et al. | Nov 2013 | B2 |
8617067 | Jain et al. | Dec 2013 | B2 |
9133024 | Phan et al. | Sep 2015 | B2 |
9867539 | Heikenfeld et al. | Jan 2018 | B2 |
20020091312 | Berner et al. | Jul 2002 | A1 |
20030135100 | Kim et al. | Jul 2003 | A1 |
20030201194 | Heller et al. | Oct 2003 | A1 |
20040215098 | Barton et al. | Oct 2004 | A1 |
20040249310 | Shartle et al. | Dec 2004 | A1 |
20040260154 | Sidelnik et al. | Dec 2004 | A1 |
20040267189 | Mavor et al. | Dec 2004 | A1 |
20050069925 | Ford et al. | Mar 2005 | A1 |
20050106713 | Phan et al. | May 2005 | A1 |
20050177035 | Botvinick et al. | Aug 2005 | A1 |
20050192528 | Tapper | Sep 2005 | A1 |
20050197554 | Polcha | Sep 2005 | A1 |
20050228297 | Banet et al. | Oct 2005 | A1 |
20050280531 | Fadem et al. | Dec 2005 | A1 |
20060009697 | Banet et al. | Jan 2006 | A1 |
20060062852 | Holmes | Mar 2006 | A1 |
20060127964 | Ford et al. | Jun 2006 | A1 |
20060253011 | Edmonson et al. | Nov 2006 | A1 |
20060254341 | Campbell | Nov 2006 | A1 |
20070027383 | Peyser et al. | Feb 2007 | A1 |
20070032731 | Lovejoy et al. | Feb 2007 | A1 |
20070179371 | Peyser et al. | Aug 2007 | A1 |
20080015494 | Santini, Jr. et al. | Jan 2008 | A1 |
20080045816 | Jang et al. | Feb 2008 | A1 |
20080080166 | Duong | Apr 2008 | A1 |
20080154179 | Cantor et al. | Jun 2008 | A1 |
20080286349 | Nomoto et al. | Nov 2008 | A1 |
20080306362 | Davis | Dec 2008 | A1 |
20090076345 | Manicka et al. | Mar 2009 | A1 |
20090159442 | Collier et al. | Jun 2009 | A1 |
20090204008 | Beilin | Aug 2009 | A1 |
20090270704 | Peyser | Oct 2009 | A1 |
20100044224 | Kataky | Feb 2010 | A1 |
20100063372 | Potts et al. | Mar 2010 | A1 |
20100130843 | Caceres Galvez et al. | May 2010 | A1 |
20100132485 | Erez et al. | Jun 2010 | A1 |
20100198521 | Haick | Aug 2010 | A1 |
20110004072 | Fletcher et al. | Jan 2011 | A1 |
20110054273 | Omoda | Mar 2011 | A1 |
20110079521 | Revol-Cavalier | Apr 2011 | A1 |
20110118656 | Eckhoff et al. | May 2011 | A1 |
20110178380 | Chowdhury | Jul 2011 | A1 |
20110196283 | Imran et al. | Aug 2011 | A1 |
20110208458 | Pinter et al. | Aug 2011 | A1 |
20110275918 | Yamashita et al. | Nov 2011 | A1 |
20120004570 | Shimizu et al. | Jan 2012 | A1 |
20120028283 | Hoss et al. | Feb 2012 | A1 |
20120119906 | Kountotsis | May 2012 | A1 |
20120123220 | Iyer et al. | May 2012 | A1 |
20120165626 | Irina et al. | Jun 2012 | A1 |
20120191147 | Rao et al. | Jul 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20120229661 | Sekiguchi et al. | Sep 2012 | A1 |
20120277697 | Haghgooie et al. | Nov 2012 | A1 |
20120285829 | Mount et al. | Nov 2012 | A1 |
20120317430 | Rahman et al. | Dec 2012 | A1 |
20130006079 | Feldman et al. | Jan 2013 | A1 |
20130010108 | Hashizume et al. | Jan 2013 | A1 |
20130013028 | Kriksunov et al. | Jan 2013 | A1 |
20130053668 | Lin | Feb 2013 | A1 |
20130079605 | Bandaru et al. | Mar 2013 | A1 |
20130099937 | Azimi | Apr 2013 | A1 |
20130108667 | Soikum et al. | May 2013 | A1 |
20130123595 | Currie et al. | May 2013 | A1 |
20130183399 | Blow et al. | Jul 2013 | A1 |
20130245388 | Rafferty et al. | Sep 2013 | A1 |
20130306491 | Briman et al. | Nov 2013 | A1 |
20130317318 | Tartz et al. | Nov 2013 | A1 |
20130317333 | Yang et al. | Nov 2013 | A1 |
20140012114 | Zevenbergen et al. | Jan 2014 | A1 |
20140025000 | Currie et al. | Jan 2014 | A1 |
20140206977 | Bahney et al. | Jul 2014 | A1 |
20140221792 | Miller et al. | Aug 2014 | A1 |
20140275862 | Kennedy | Sep 2014 | A1 |
20140276220 | Briscoe et al. | Sep 2014 | A1 |
20140343371 | Sowers, II et al. | Nov 2014 | A1 |
20150057515 | Hagen et al. | Feb 2015 | A1 |
20150112164 | Heikenfeld et al. | Apr 2015 | A1 |
20150112165 | Heikenfeld | Apr 2015 | A1 |
20150289820 | Miller et al. | Apr 2015 | A1 |
20160058354 | Phan et al. | Mar 2016 | A1 |
20160066828 | Phan et al. | Mar 2016 | A1 |
20160157768 | Braig et al. | Jun 2016 | A1 |
20160256055 | Okamura | Sep 2016 | A1 |
20170100035 | Heikenfeld | Apr 2017 | A1 |
20170100071 | Heikenfeld | Apr 2017 | A1 |
20170215773 | Heikenfeld et al. | Aug 2017 | A1 |
Number | Date | Country |
---|---|---|
0282349 | Sep 1988 | EP |
0453283 | Oct 1991 | EP |
1575010 | Sep 2005 | EP |
1637889 | Mar 2006 | EP |
2551784 | Jan 2013 | EP |
2783725 | Oct 2014 | EP |
1990011519 | Oct 1990 | WO |
1994014062 | Jun 1994 | WO |
2000014535 | Mar 2000 | WO |
2001088525 | Nov 2001 | WO |
2006133101 | Dec 2006 | WO |
2007097754 | Aug 2007 | WO |
2007146047 | Dec 2007 | WO |
2008058014 | May 2008 | WO |
2008083687 | Jul 2008 | WO |
2008095940 | Aug 2008 | WO |
2009004001 | Jan 2009 | WO |
2009052321 | Apr 2009 | WO |
2010017578 | Feb 2010 | WO |
WO 2010130861 | Nov 2010 | WO |
2011008581 | Jan 2011 | WO |
2011117952 | Sep 2011 | WO |
2013111409 | Aug 2013 | WO |
2013181436 | Dec 2013 | WO |
2014001577 | Jan 2014 | WO |
2014025430 | May 2014 | WO |
2015058065 | Apr 2015 | WO |
2016007944 | Jan 2016 | WO |
2016049019 | Mar 2016 | WO |
2016090189 | Jun 2016 | WO |
2016130905 | Aug 2016 | WO |
2016138087 | Sep 2016 | WO |
2017019602 | Feb 2017 | WO |
2017070640 | Apr 2017 | WO |
Entry |
---|
BurnCentreCare, “About Burned Skin”, Nov. 4, 2010, http://burncentrecare.co.uk/about_burned_skin.html. |
Schweber, Bill, “What . . . You're Using Lasers for Area Heating?”, Feb. 16, 2015, https://www.eetimes.com/author.asp?section_id=36&doc_id=1325651. |
Farzana Abanty, “Temperature of a Healthy Human (Skin Temperature)”, Aug. 10, 2001, https://hypertextbook.com/facts/2001/AbantyFarzana.shtml. |
International Searching Authority, Search Report issued in corresponding International Application No. PCT/US2016/43771 dated Dec. 8, 2016, 4 pages. |
International Searching Authority, Written Opinion issued in corresponding International Application No. PCT/US2016/43771 dated Dec. 8, 2016, 9 pages. |
International Searching Authority, Search Report and Written Opinion issued in corresponding International Application No. PCT/US2016/58356 dated Jan. 6, 2017, 15 pages. |
International Searching Authority, Search Report and Written Opinion issued in corresponding International Application No. PCT/US2016/58357 dated Jan. 19, 2017, 9 pages. |
International Searching Authority, Search Report and Written Opinion issued in corresponding International Application No. PCT/US2017/047808 dated Nov. 6, 2017, 10 pages. |
Number | Date | Country | |
---|---|---|---|
20160374598 A1 | Dec 2016 | US |
Number | Date | Country | |
---|---|---|---|
62185769 | Jun 2015 | US |